Trial Profile
Evaluation of the Effect of Two Doses of AMR101 (Ethyl Icosapentate) on Fasting Serum Triglyceride Levels in Patients With Persistent High Triglyceride Levels (greater than or equal to 200 mg/dL and less than 500 mg/dL) Despite Statin Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Dyslipidaemias; Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Acronyms ANCHOR
- Sponsors Amarin Corporation
- 06 Jun 2019 Results of post hoc analysis to examine the effects of icosapent ethyl on triglycerides,high-sensitivity C-reactive protein in the subgroup of patients from ANCHOR published in the American Journal of Cardiology
- 28 Nov 2018 According to a Cardax Pharmaceuticals media release, Paresh N. Soni, M.D., Ph.D led the development of this clinical trial and regulatory strategy.
- 12 Apr 2018 Results published in an Amarin Corporation Media Release